Fast Market Research

New Market Report: Eylea (Microvascular Complications of Diabetes) - Forecast and Market Analysis to 2022

Recently published research from GlobalData, "Eylea (Microvascular Complications of Diabetes) - Forecast and Market Analysis to 2022", is now available at Fast Market Research

 

Boston, MA -- (ReleaseWire) -- 02/10/2014 -- Eylea (Microvascular Complications of Diabetes) - Forecast and Market Analysis to 2022

Summary

The entire market for microvascular complications of diabetes (MCD) - diabetic nephropathy, retinopathy, and neuropathy - is facing an extremely high level of unmet need across the 7MM (US, 5EU and Japan). Despite its enormous potential, the MCD market is facing the major global barrier in the sparsely populated pipeline. The diabetic retinopathy segment of the market has recently seen rapid uptake of novel anti-VEGF therapies and is experiencing a strong growth. On the other hand, the diabetic neuropathy and nephropathy segments face the barrier in and increasing number of generic competitors.

View Full Report Details and Table of Contents

Eylea is a fusion protein consisting of VEGF-binding portions. It is specifically designed to bind to all isoforms of VEGF-A, VEGF-B and placental growth factor (PGF), leading to their removal from circulation. Decrease in VEGF-A levels causes a decrease in macular edema by restricting the growth of new blood vessels.

Scope

- Overview of MCD, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Eylea including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Eylea for the top seven countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.

Reasons to Get This Report

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for MCD
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Eylea performance
- Obtain sales forecast for Eylea from 2012-2022 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Atrasentan (Microvascular Complications of Diabetes) - Forecast and Market Analysis to 2022
- Optina (Microvascular Complications of Diabetes) - Forecast and Market Analysis to 2022
- Ranirestat (Microvascular Complications of Diabetes) - Forecast and Market Analysis to 2022
- Avastin (Microvascular Complications of Diabetes) - Forecast and Market Analysis to 2022
- Lucentis (Microvascular Complications of Diabetes) - Forecast and Market Analysis to 2022
- PharmaPoint: Microvascular Complications of Diabetes - Current and Future Players
- PharmaPoint: Type 2 Diabetes - Japan Drug Forecast and Market Analysis to 2022
- PharmaPoint: Type 2 Diabetes - Spain Drug Forecast and Market Analysis to 2022
- PharmaPoint: Type 2 Diabetes - UK Drug Forecast and Market Analysis to 2022
- PharmaPoint: Type 2 Diabetes - Germany Drug Forecast and Market Analysis to 2022